Platinum-based chemotherapy (PBC) in combination with the 3 rd generation drugs is the first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy is severely hampered by grade 3-4 toxicities. Nucleotide excision repair (NER) pathway is the main mechanism of removing platinum-induced DNA adducts that contribute to the toxicity and outcome of PBC. We analyzed data from 710 Chinese NSCLC patients treated with PBC and assessed the associations of 25 potentially functional single nucleotide polymorphisms (SNPs) in nine NER core genes with overall, gastrointestinal and hematologic toxicities. Through a two-phase study, we found that ERCC4 rs1799798 was significantly associated with overall and gastrointestinal toxicities [all patients: GA/AA vs. GG, odds ratio (OR) adj 51.61 and 2.35, 95% confidence interval (CI)51.11-2.33 and 1.25-4.41, and P adj 50.012 and 0.008, respectively]. Our prediction model for the overall toxicity incorporating rs1799798 demonstrated a significant increase in the area under the curve (AUC) value, compared to that for clinical factors only (all patients: AUC 5 0.61 vs. 0.59, 95% CI 5 0.57-0.65 vs. 0.55-0.63, P 5 0.010). Furthermore, the ERCC4 rs1799798 A allele was associated with lower ERCC4 mRNA expression levels according to the expression quantitative trait loci (eQTL) analysis. Our study provided some new clue in future development of biomarkers for assessing toxicity and outcomes of platinum drugs in lung cancer treatment.
Introduction
Lung cancer is the leading cause of cancer mortality worldwide, with an estimation of 1.8 million new cases and 1.59 million deaths in 2012, 1 of which non-small cell lung cancer (NSCLC) represents approximately 85% of the total incident cases. 2 Over the past decade, platinum-based chemotherapy (PBC) has continued to be the standard care for patients with advanced-stage NSCLC, 3 with a modest response rate of 30-50%
4,5 and a 5-year survival of <15%.
6
The anti-neoplastic effect of PBC is through the formation of inter-or intra-strand DNA adducts that result in distortion and lesion of the DNA, 7 which further activate apoptotic pathways that lead to cell death. 8 The cytotoxic profile of PBC may cause unpredictable and occasionally severe adverse effects that impair the therapy adherence and quality of life of the patients. Clinical studies have shown marked differences in the incidence and severity of toxicities among patients treated with PBC. 9, 10 Therefore, it is urgent to identify predictive and prognostic markers for patients who undergo PBC. Besides the established clinical-related risk factors for the toxicity, such as elderly age, poor performance status and histologic stage, single nucleotide polymorphisms (SNPs) in DNA repair pathways may also contribute to the observed variation in response to PBC.
11,12
An individual's DNA repair capacity plays a vital role in maintaining genomic stability by three major mechanisms: nucleotide excision repair (NER), base excision repair and mismatch repair. NER is mainly responsible for the repair of platinum-DNA adducts, including all three types of DNA intrastrand crosslinks (1,2-d(ApG), 1,2-d(GpG), and 1,3-d(GpNpG)). 11 NER uses a cut-and-paste method in a sequential order involving the collaborative functions of 20-30 proteins. 13 The binding of the XPC/HHR23B complex to the entire repair protein apparatus signifies the initial step of damage recognition, followed by opening the DNA helix around the lesion, being orchestrated by XPA 14 and employing helicases of the transcription factor II H (TFIIH) complex (including ERCC3 and ERCC2 helicases). 15 Subsequently, the dual incision of the lesion takes place with the facilitation of the ERCC5 and ERCC1/ERCC4 complex. Finally, the gapfilling repair synthesis is collaboratively performed with replication protein A, replication factor C, proliferating cell nuclear antigen and DNA polymerase d and E. 16 Theoretically, suboptimal DNA repair capacity may either increase individual's positive response to chemotherapy by promoting cancer cell death (i.e., the treatment effect) or lead to an increased toxicity because of inefficient removal of DNA lesions in normal bystander cells exposed to the treatment, which eventually results in a high rate of cell death in normal tissue as well (i.e., the side-effects). Therefore, it is conceivable that genetic variation in NER pathway genes may serve as a prognostic factor for PBC-induced toxicity in NSCLC patients.
In the present study, we assessed predictive and prognostic effects of the selected common genetic variants on PBCinduced toxicity by analyzing 25 potentially regulatory SNPs (rSNPs) in nine core NER genes (ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, RAD23B, XPA, XPC and XPE) in 710 patients with advanced NSCLC. All these 25 rSNPs are predicted by bioinformatics tools to be potentially functional in regulating gene expression (Supporting Information, Table S1 ).
Materials and Methods

Study population
The present study included patients diagnosed with histologically advanced NSCLC from Fudan University Shanghai Cancer Center (FUSCC). The discovery group included 355 patients recruited between February 2009 and February 2012, whereas the replication group consisted of 355 patients recruited from March 2012 to November 2013. Further details about the recruitment have been described elsewhere. 17 In brief, the recruited patients were unrelated Han
Chinese with inoperable TNM stages III to IV tumors of NSCLC without prior history of cancer other than in situ carcinoma; received PBC as the first-line treatment; the Eastern Cooperative Oncology Group performance (ECOG) status 0 to 2 with normal blood and uronoscopy laboratory test results; no active infection, serious medical or psychological conditions that might affect adverse events; and at least two chemotherapy cycles except for those who developed severe toxicity after one cycle. Clinical data, including age at treatment, sex, smoking status, ECOG performance, TNM stage, histological type and grade, chemotherapy regimen options and radiotherapy treatment, were collected from patients' medical records. A written informed consent was obtained from each participant, and their blood samples were collected and stored in the FUSCC Tissue Bank in the hospital. This research protocol was approved by the Institutional Review Board of FUSCC, and all the methods were implemented in accordance with relevant guidelines and regulations.
Toxicity data
Patients' toxicity profiles were evaluated through examination of their laboratory test results, when toxicity events occurred.
What's new?
The toxicity of platinum-based chemotherapy (PBC) causes unpredictable adverse effects among non-small cell lung cancer (NSCLC) patients. DNA repair capacity, particularly the nucleotide excision repair (NER), has been associated with PBC efficacy and toxicity. After assessing 25 potentially functional regulatory single nucleotide polymorphisms (SNPs) in nine core NER genes in 710 Chinese NSCLC patients, the authors found a novel ERCC4 variant that was significantly associated with overall and gastrointestinal toxicities induced by PBC. This study provides clues that may help to unravel the molecular mechanisms underlying PBC-induced toxicity and develop biomarkers for predicting toxicity in patients with advanced NSCLC.
The chemotherapy-related toxicities were assessed twice a week until 1 week after the completion of chemotherapy, including overall, gastrointestinal (GI) (including nausea, vomiting and diarrhea) and hematologic toxicity (including leukocytopenia, agranulocytosis, anemia and thrombocytopenia). The grade of toxicity was recorded according to the National Cancer Institute Common Toxicity Criteria, version 3.0. 18 However, due to the limited information in the medical reports, details about the grade 3 or 4 classified GI toxicities and the occurring time of the toxicity events were not available.
Chemotherapy regime
All patients included in the present study were having inoperable late-stage tumors and thus had received first-line platinum-based chemotherapy. The drugs paired with platinum formed 10 combinations: cisplatin (75 mg/m 
SNP selection
To specifically explore the association between rSNPs in the NER core genes and toxicity outcome of NSCLC patients subjected to PBC, all the rSNPs were queried from the NER gene regions under the study by using SNP/GeneView in dbSNP database (http://www.ncbi.nlm.nih.gov/snp/) with the GRCh38 reference build of the human genome. A total of 25 rSNPs in eight (out of nine, and none found in DDB1/XPE) NER core genes were chosen, with detailed characteristics of all investigated genes and rSNPs shown in Supporting Information, Table S1 .
SNPseq genotyping
Genomic DNA was extracted from the whole blood of all study subjects by using DNA Blood Mini Kit (Qiagen, Valencia, CA). The purity [optical density (OD) 260/280 at 1.7-2.0] and concentration (>20 ng/ll) met the sequencing requirements. Genotyping of all rSNPs was conducted by FastTarget, a next generation sequencing-based method using Illumina Miseq2000 Platform (2 3 250 bp, Illumina, CA, USA). Prior to sequencing, 5% of the samples were randomly selected and subjected to 1% agarose gel electrophoresis for quality control. Genomic regions containing investigating rSNPs were amplified using the FastTarget TM technology (Genesky Biotechnologies Inc, Shanghai, China). After multiple PCR reactions, DNA fragments were ligated with the adaptor by using Q5 DNA polymerase Kit (New England Biolabs, MA, USA), and further purified by Agencourt AMPure XP (Beckman Coulter, CA, USA).
Next-generation sequencing of the amplification products was carried out by MiSeq 2000 Sequencer (Illumina, Inc., San Diego, CA, USA), following the manufacturer's standard protocols. Output sequence data were trimmed and then compared to fragment reference sequences (hg19) using the Blat program. Burrows-Wheeler Aligner (BWA, V 0.7.5a) was used to map the reads, 19 followed by Sequence Alignment Map (SAM)-to-BAM conversion. Sorting and removal of duplicates were done using SAM tools (v0.1.19). 20 Combined rSNP calling was performed on the resulting BAM files using Genome Analysis Toolkit (GATK, https://software.broadinstitute.org/gatk/best-practices/) and VarScan programs. 21 Finally SNP annotation was done by the Annovar program. 22 The eQTL analysis GTEx portal was used to assess the correlation between toxicity-related genetic variants and NER gene mRNA expression levels (http://www.gtexportal.org/home/). The latest version (Oct. 2015 release) includes genotype data from approximately 450 donors and 9600 RNA-seq samples across 51 tissues and 2 cell lines, with sufficient power to detect eQTL in 44 tissues. The associations of genetic variant and gene expression are investigated in various tissue types.
Statistical analysis
We used the v 2 test for comparisons between individuals with severe toxicity (NCI-CTC grades 3-4) and those with mild or no toxicity (NCI-CTC grades 0-2) as well as for adverse events that were dichotomized by presence or absence of (a) any grade 3-4 toxicity, and (b) any grade 3-4 GI or hematologic toxicities. The association between each genetic variant and severe chemotherapy toxicity was assessed by odds ratios (ORs) and their 95% confidence intervals (CIs) estimated by unconditional logistic regression models with or without adjustment for age at treatment, sex, smoking status, TNM stage, BMI, histological type, histologic grade, ECOG performance status, chemotherapy regimens and palliative radiotherapy. For toxicity prediction model construction, independent predictors including selected clinical variables and genetic variant were selected by the backward-stepwise logistic regression process. The receiver Cancer Epidemiology operating characteristic curve (ROC) analysis with the area under the curve (AUC) value was used to compare sensitivity and specificity of the toxicity prediction by the selected parameters. All statistical analyses were performed using the SAS software, version 9.4 (SAS Institute, Inc., Cary, NC). Unless stated otherwise, all p values were two-sided with a significance level of p < 0.05.
Results
Characteristics of the study population
The analysis included 710 NSCLC patients treated with PBC as the first-line chemotherapy. The demographic, clinical characteristics and main toxicity events are summarized in 
NER rSNPs and grade-3 or 24 toxicities
We performed a two-stage screening to evaluate the association of rSNPs in the eight NER core genes with grade-3 or 24 toxicities. In the discovery group, we performed multivariate logistic regression analysis to assess the associations of these rSNPs with toxicities. We found that three SNPs were associated with overall toxicity, four SNPs were associated with hematologic toxicity, and four SNPs associated with GI toxicity (p < 0.1 by the trend test or genotype test, Figure 1 , Supporting Information, Table S2-4). The positive associations in the discovery group were further validated in the replication group using the same significance threshold criteria. Out of all the SNPs that passed the significance threshold in the discovery phase, only ERCC4 rs1799798 SNP remained to be significantly associated with overall and GI toxicity. Patients with ERCC5 rs751402 AG and AG/AA genotypes exhibited a significantly higher risk of hematologic toxicity in the discovery group, when compared to the GG genotype, but not in the validation set ( Fig. 1, ). It appears that based on the sample size of the present study, only ERCC4 rs1799798 was consistently associated with GI and overall toxicity in all the datasets.
NER variant-based prediction model for PBC-induced toxicity in NSCLC patients
The cumulative effects of toxicity-associated rSNPs and respective clinical risk factors were further examined by comparing the area under the curve (AUC) of the two. To assess the discriminative accuracy of the prediction models, we calculated AUC of the ROC curves. All the variables were selected using a backward-stepwise logistic regression process for inclusion in the prediction model. The selected variables were carboplatin-based therapy, pemetrexed and ERCC4 rs1799798 GA/AA for overall toxicity; and TNM, BMI, gemcitabine, pemetrexed and ERCC4 rs1799798 GA/AA for GI toxicity (Supporting Information, Table S5 ). In the prediction model of overall toxicity, the addition of ERCC4 rs1799798 GA/AA significantly increased the AUC to 0.61 (95% CI5 0.57-0.65) in all patients, compared to the model that only included the clinical variables (AUC5 0.59; 95% CI5 0.55-0.63; P ChiSq 5 0.010) (Fig. 2a , Supporting Information, Table  S6 ). However, the ROC prediction model incorporating the risk genotype for overall toxicity was not significantly different from that incorporating only clinical factor in the discovery set. For GI toxicity prediction, the AUC for the model with the addition of ERCC4 rs1799798 GA/AA increased slightly, compared to that of the model with clinical variables (Fig. 2b) . The AUC values of ROC curves for the overall and GI toxicity in all datasets are listed in Supporting Information, Table S6 . Given the modest AUC values in general and the limited sample size, these findings indicated that ERCC4 rs1799798 might independently contribute to the partial prediction power of overall toxicity in PBCtreated NSCLC patients.
Stratified analysis for associations between the risk genotypes and PBC toxicity
Stratified analysis was also performed to assess potential effects of different demographic or clinical variables on the toxicity outcomes associated with risk genotypes of ERCC4. Overall, the ERCC4 rs1799798 GA/AA carriers exhibited an increased risk of overall toxicity in subgroups of elderly patients (>58 years), non-smokers, poorly differentiated tumors, adenocarcinoma, recipients of gemcitabine, pemetrexed, and cisplatin-based chemotherapies, compared to the GG carriers (Table 3 ). The carriers of the risk A allele had an increased risk of GI toxicity in subgroups of older, nonsmokers, ECOG status 2, well-moderately differentiated, adenocarcinoma, no radiotherapy, and recipients of pemetrexed (Table 3) .
NER rSNPs and grade-3 or 24 hematologic toxicity
The associations of NER rSNPs with leukocytopenia, agranulocytosis, anemia and thrombocytopenia were further evaluated by univariate and multivariate logistic regression analyses. Under a dominant model, carriers of the ERCC1 rs3212924 G, rs3212986 A alleles and RAD23 rs7041137 T allele exhibited a significantly increased risk of leukocytopenia (ERCC1: OR adj 51.77 and 1.63, 95% CI 5 1.13-2.76 and 1.03-2.57, P adj 50.013 and 0.036, respectively; RAD23: OR adj 52.08, 95% CI 5 1.34-3.24, P adj 50.001), while carriers of the ERCC3 rs13385611 C allele exhibited a similar association under a recessive model (OR adj 55.64, 95% CI 5 1.68-18.96, P adj 50.005) ( Table 4) . With a relatively small number of incidents, a borderline protective effect of thrombocytopenia was found in patients carrying ERCC5 rs873601 GA and GA/GG genotypes (OR adj 50.35 and 0.39, 95% CI 5 0.13-0.91 and 0.17-0.91, P adj 50.031 and 0.029, respectively), compared to those carrying the AA genotype. No significant association was found between these genetic variants and anemia or agranulocytosis.
Correlations between ERCC4 risk genotypes and mRNA expression levels
To examine the genotypic effect of toxicity-associated risk rSNPs on the gene expression, the eQTL analysis of the ERCC4 risk SNP rs1799798 was further performed by using publically available database. In the GTEx samples of transformed fibroblast cells, we found that the ERCC4 rs1799798 A allele was significantly associated with a lower mRNA level of ERCC4 (p 5 0.81 3 10 28 , effect size 5 20.35, Fig. 3a ). In addition, significant difference in gene expression levels regulated by this SNP was also found in tissues of esophagus (gastroesophageal junction), thyroid, colon and brain (p 5 0.0013, effect size 5 20.40, Fig. 3b ). Taken together, the observed association between ERCC4 rs1799798 and overall and GI toxicity may be explained by the difference in gene expression levels regulated by these two alleles. Therefore, it can be speculated that the reduction in ERCC4 expression levels could be associated with a higher toxicity and thus an unfavorable clinical outcome.
Discussion
PBC in conjunction with other cytotoxic agents has been used as the first-line therapy for advanced NSCLC, accompanied by variation in severe side effects among the patients, which hamper treatment outcome. [23] [24] [25] The variation in these toxicities is likely due to variation in the NER pathway that is responsible for the removal of PBC-induced DNA damage, leading to variation in response to toxic platinum agents. DNA repair capacity, particularly of the NER pathway, has been associated with the PBC efficacy and toxicity, and numerous studies have indicated that genetic variations, such as SNPs in the NER pathway genes, may modulate repair functions and cellular apoptosis, prompting individual variation in toxicity outcomes of PBC. 26, 27 Published studies on NER pathway variants and PBC toxicity in NSCLC patients have mainly focused on missense variants, with very few investigating a group of core genes in the pathway or considering LD between the variants or noncoding variants. 24, 28, 29 In the present study, we employed a hypothesis-based approach with a main focus on independent regulatory variants with predicted biological functions. Based on a two-phase screening design, we observed that under a dominant genetic model the ERCC4 rs1799798 SNP had a significant effect on both overall and GI toxicity outcomes in advanced Chinese NSCLC patients treated with PBC, it is possible that the rs1799798 A allele associated with a higher risk of overall toxicity was driven by its association with GI toxicity ( Table 2 ). The association with this risk SNP seems to be robust in discovery, replication and the combined datasets, but the prediction model for overall toxicity incorporating this risk SNP exhibited a moderate increase in the AUC value in all patients dataset, compared to the clinical variable-based model (Supporting Information, Table S6 ). This SNP has previously been found to be associated with the overall survival of these patients (Supporting Information, Fig. S2 ). It is possible that the increased risk of death observed in those patients carrying the risk allele was exacerbated by the consequence of the higher toxicity. ERCC4 participates in the removal of DNA inter-strand cross-links and double-stranded breaks, and therefore SNPs in ERCC4 may impact the repair capacity and thus affect chemotherapy outcome. The rSNP rs1799798 resides in an intron of the ERCC4 gene without a linkage to any other SNPs within a 1 Mb window ( Supporting Information, Fig. S1 ). Bioinformatics analysis predicted a functional role of this SNP to be in the ELF-1 binding site. 30 The present study also suggested that ERCC4 variant might affect overall, GI and hematologic toxicities based on different demographic or clinical characteristics. For instance, overall and GI toxicities of patients carrying ERCC4 rs1799798 GA/AA genotypes were more evident in subgroups of older, non-smokers, adenocarcinoma and recipients of gemcitabine, pemetrexed chemotherapies. Such effect of ERCC4 rs1799798 was more apparent in subgroups of gemcitabine, cisplatin-based chemotherapy and low histologic grade for overall toxicity but subgroups of high histologic grade and no radiotherapy for GI toxicities. The association of ERCC4 rs1799798 in the non-radiotherapy subgroup indicates that this SNP might contribute to the observed GI toxicity independent of radiotherapy ( Table 3) . We also identified additional NER variants to be associated with various types of hematologic toxicity (Table 4 ). Due to the relatively small sample size in some subgroups or toxicity incidence, these results need to be further validated in larger study populations.
Finally, there are some inherent limitations in the present study. First, the recruitment of patients treated in the same hospital may lead to selection bias and may not be generalizable to other patient populations; therefore interpretation of our results needs to be dealt with caution, and additional replication studies in different patient populations are desired. Second, with the aim of studying rSNPs, we did not incorporate the coding region SNPs with known effects. This might weaken the power of our ROC prediction models. Third, multiple testing correction was not conducted in the present study, because this was an exploratory study with limited study power. Last, because it is a retrospective study with a relatively small sample size, further prospective studies with large populations are warranted to validate our findings.
In conclusion, the present study provided some evidence that rSNP in the NER core genes may modulate PBCinduced toxicity. This explorative study may serve as the basis for further replicative and functional studies to unravel the molecular mechanisms underlying PBC-induced toxicity, which may lead to development of useful biomarkers for predicting platinum-based chemotherapy toxicity in patients with advanced NSCLC.
